05.04.2018 • News

CB&I Wins China Projects

CB&I Wins China Projects (c) CBI
CB&I Wins China Projects (c) CBI

US engineering contractor CB&I has won three separate contracts in China. The first from Hainan Huasheng New Material Technology is for the license and engineering design for a diphenyl carbonate (DPC) plant in Hainan province. The unit will use technology licensed from Italy’s Versalis to produce DPC, which is a raw material used to make PC. Capacity details were not disclosed.

CB&I’s second contract is for the license and process design engineering of a 300,000 t/y PP plant for CNOOC Ningbo Daxie Petrochemical. The facility in Ningbo will use the engineering contractor’s Novolen technology and proprietary Novolen High Performance catalyst.

“By licensing this technology, CNOOC Daxie will be able to produce a wide range of polypropylene products and meet China’s increasing demand for these high-end products,” said Daniel McCarthy, CB&I’s executive vice president of technology.

Lastly, Jinneng Science & Technology chose the US contractor to supply a license and engineering design of a propane dehydrogenation (PDH) plant in Qingdao, Shandong province. The unit, which will produce 900,000 t/y of propylene, will be based on CB&I’s Catofin technology and catalyst as well as heat generating material from Swiss partner Clariant. CB&I said the plant will be the world’s largest single-train PDH facility when it is operational.

Start-up dates for each of the plants as well as financial terms of the contracts were not revealed.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read